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Abstract
Introduction
Policy, environmental, and systems-level interventions 
are part of a comprehensive approach to managing high 
blood pressure and high cholesterol, which are key risk 
factors for heart disease and stroke. In this qualitative 
case study, we identified clinical practices in health care 
organizations  that  used  policy,  environmental,  or  sys-
tems-level  interventions  to  improve  patient  outcomes 
for these conditions. Our 4 objectives were to describe 1) 
policy, environmental, and systems-level interventions; 2) 
enabling factors and barriers that affected implementa-
tion; 3) methods for evaluating the success of the interven-
tion; and 4) lessons learned from the health care practices 
that implemented these interventions.
Methods
Through  literature  review  and  expert  guidance,  we 
identified 34 health care practices that used policy, envi-
ronmental,  and  systems-level  interventions  to  manage 
high  blood  pressure  and  high  cholesterol.  In  2003,  we 
conducted case study interviews with key informants for 
9  health  care  practices  that  1)  demonstrated  improved 
patient  outcomes  for  blood  pressure  or  cholesterol;  2) 
implemented the interventions for at least 1 year; and 3) 
remained  committed  to  sustaining  or  institutionalizing 
interventions.  We  taped  and  transcribed  the  interviews 
and used Centers for Disease Control and Promotion EZ-
Text  software  (www.cdc.gov/hiv/software/ez-text.htm)  to 
code, categorize, and analyze the responses.
Results
The  health  care  practices  we  studied  implemented 
specialized lipid clinics, disease management programs, 
physician  reminder  systems,  and  participation  in  the 
Health Resources and Services Administration’s Bureau 
of Primary Care Health Disparities Collaboratives. All 
practices  used  comprehensive  systems  for  patient  care 
that were well-defined, measurable, and linked to desir-
able patient outcomes. Most relied on data systems to 
identify patients targeted for the interventions and prac-
tice  areas  that  needed  improvement,  and  to  track  the 
progress of patients and practitioners in meeting goals. 
Factors  contributing  to  success  included  support  for 
patient  self-management,  interventions  integrated  into 
the practice’s daily work flow to make implementation 
easier  for  staff,  leadership  and  staff  commitment,  and 
community involvement.
Conclusion
Comprehensive  policy,  environmental,  and  systems-
level  interventions  for  patient  care  can  be  effective  in 
controlling chronic conditions such as high blood pressure 
and high cholesterol.
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Introduction
Coronary heart disease and stroke are the first and third 
leading causes of death in the United States (1) and major 
causes of disability (1,2). The American Heart Association 
and the American Stroke Association estimate that the 
total  direct  and  indirect  cost  of  cardiovascular  disease 
(CVD) in the United States in 2007 was $438 billion (2). 
Much of the burden of heart disease and stroke could be 
eliminated by preventing or reducing 7 major risk factors 
— high blood pressure, high cholesterol, obesity, tobacco 
use, diabetes, physical inactivity, and poor diet (3,4). For 
example, a reduction in systolic blood pressure of 12 to 13 
mm Hg over 4 years of follow-up can reduce heart attacks 
by  21%,  strokes  by  37%,  and  all  deaths  from  coronary 
vascular disease by 25% (5). Furthermore, a 10% decrease 
in total cholesterol may reduce the incidence of coronary 
heart disease by as much as 30% (6,7). However, only an 
estimated 31% of adults with high blood pressure (8) and 
18% of those with high cholesterol (9) have these condi-
tions under control. The 2004 estimated prevalence of high 
blood pressure at or above 140/90 mm Hg in U.S. adults 
aged 20 and older was 33.6%, and total cholesterol at or 
above 200 mg/dL was 48.4% (2). The Healthy People 2010 
targets are to reduce the proportion of adults with high 
blood pressure to 16% and to lower the proportion of adults 
with elevated total cholesterol to 17% (10).
Why is it such a challenge to prevent and control high 
blood pressure and high cholesterol? The literature cites 
many  reasons  (11-15).  Some  articles  focus  on  patient-
related  factors,  such  as  noncompliance  with  treatment 
regimens  because  of  medication  side  effects,  complexity 
of the drug regimen(s), and lack of awareness of the need 
for long-term therapy (11-13). Others focus on the failure 
of physicians to consistently comply with evidence-based 
guidelines  (14).  According  to  Wagner,  Austin,  and  Von 
Korff, clinical practices are not structured to adequately 
care for patients with chronic conditions (15):
Medical practices, especially those in primary care, 
are  generally  organized  to  respond  to  the  acute 
and urgent needs of their patients, or symptom-
relieving treatments. . . . This leaves little time or 
intellectual energy for addressing the less urgent, 
but  nevertheless  predictable,  needs  of  patients 
with chronic illness in managing their conditions 
and preventing deleterious sequelae.
Policy, environmental, and systems-level (PES) interven-
tions constitute a paradigm shift in clinical care from ear-
lier health care models and represent an ecological model 
that links PES changes with behavior changes at the indi-
vidual level to prevent heart disease and stroke (16-18). 
Policy interventions include laws, regulations, and formal 
and informal rules adopted within specific organizations 
(19).  For  example,  health  care  organizations  can  have 
treatment policies to implement evidence-based national 
clinical guidelines such as those of the Seventh Report of 
the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure (JNC 
7) (20); the Third Report of the Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in 
Adults (ATP III Final Report) (21); and the 2002 update 
to the American Heart Association (AHA) guidelines (22) 
and  the  2001  update  to  the   AHA/American  College  of 
Cardiology guidelines (23).
Environmental interventions are changes to the econom-
ic, social, or physical environments (19). Examples include 
making community resources available and known to the 
public and creating an environment that allows people to 
make healthier choices.
Systems-level  interventions  are  changes  affecting  the 
way an organizational system operates. Within the health 
care setting, these interventions generally focus on chang-
ing the ways in which health services are delivered and 
may  include  delegating  responsibility  for  key  care  func-
tions to nonphysician members of the health care practice, 
putting systems in place to ensure appropriate follow-up 
with patients, and providing regular feedback to physicians 
on how well they manage their patients’ conditions (24).
A 1996 literature review (15) examined comprehensive 
approaches to reorganizing the delivery of care to improve 
the outcomes of patients with chronic illness. The review’s 
authors  noted  that  successful  interventions  shared  the 
following elements: 1) explicit protocols based on evidence-
based  guidelines;  2)  practice  organization  to  meet  the 
needs of patients who require more time, a broad array of 
resources, and closer follow-up; 3) systematic attention to 
providing patients with information for behavioral change; 
4) ready access to necessary expertise; and 5) supportive 
information  systems  (15).  These  elements,  which  also 
could  be  considered  PES  interventions,  are  reflected  in 
Edward H. Wagner’s Chronic Care Model (25). This model 
for improving the care of patients with chronic disease has 
2  Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2008/jul/07_0218.htm
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, 
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only 
and does not imply endorsement by any of the groups named above.essential elements grouped in 6 areas: 1) the community 
(resources and policies), 2) the health care system (organi-
zation of health care), 3) support for patient self-manage-
ment, 4) design for delivering health services to patients, 
5) support for physician decisions, and 6) clinical informa-
tion systems.
In a 1997 review of interventions to prevent cardiopul-
monary disorders among patients in health care settings, 
Ockene  et  al  (26),  concluded  that  traditional  education 
and training programs for health care providers combined 
with reminders systems, feedback to providers, and prac-
tice guidelines are most effective for delivering preventive 
interventions.  They  also  found  that  the  effectiveness  of 
providers is optimized when the intervention uses a team 
of both nonphysicians and physicians to counsel patients 
on  prevention  and  when  providers  support  the  control 
of risk factors through multiple patient visits, follow-up 
telephone calls to the patient, or referrals to specialists as 
appropriate.
We  have  identified  other  promising  quasi- 
experimental  or  experimental  studies  published  from 
1997  through  2007  describing  interventions  in  health 
care settings that contribute to preventing and control-
ling high blood pressure, high cholesterol, heart disease, 
and stroke (14,20-23,27-72). Elements of interventions 
that  showed  improvement  in  outcomes  for  high  blood 
pressure or high cholesterol included 1) providers that 
adhere  to  standardized  protocols  that  are  consistent 
with  evidence-based  national  guidelines  (20-23,28-44); 
2)  multidisciplinary  clinical  care  teams  that  deliver   
elements of quality patient care, such as routine and con-
sistent  screening,  assessment,  counseling,  and  patient 
follow-up contacts, to control risk factors (32,33,38,45-
48);  3)  treatment  and  prevention  clinics  that  deliver 
focused  management  of  care  (31,33-37,49-54);  4)  elec-
tronic  medical  record  systems,  automatic  prescription 
systems,  and  paper  and  electronic  reminder  systems 
for  health  care  providers  (14,55-63);  and  5)  patient   
education (61,62,65-71). National treatment guidelines 
recommend  that  clinical  prevention  and  treatment 
  services  include  these  5  elements  (54,55,58,59,63,64, 
68,71).
Purpose of study 
The  purpose  of  our  case  study  was  to  identify  and 
describe promising health care practices (PHPs) and the 
PES  interventions  these  practices  used  to  control  high 
blood pressure and high cholesterol. We defined a PHP 
as one that had practice-based data showing positive out-
comes from interventions to reduce risk factors related to 
heart disease and stroke but whose data may not yet have 
been tested in controlled studies to allow for generalizable 
results (16). We also identified the strategies that led to 
successful  adoption  and  implementation  of  these  PES 
interventions, the methods used to evaluate progress, and 
lessons learned.
Methods
We searched peer-reviewed literature databases (ABI/
Inform, Ann Arbor, Michigan; Lexis/Nexis, New York, 
New York; OVID, New York, New York; and the National 
Library of Medicine’s PubMed, Bethesda, Maryland) for 
articles  published  from  1992  through  2003  to  identify 
studies of PES interventions in health care settings that 
were  focused  on  the  prevention  of  heart  disease  and 
stroke. We also used Google (www.google.com) to iden-
tify practices implementing PES interventions that had 
received special recognition, such as the C. Everett Koop 
award for exemplary health care programs. In addition, 
we selected a variety of experts from among participants 
in national conferences and our own professional con-
tacts, including staff from state health departments, rep-
resentatives from business groups and health associa-
tions, and researchers, to identify PHPs that were using 
PES interventions. The search generated 644 studies of 
PHPs  that  used  PES  interventions.  We  narrowed  the 
list  to  34  studies  that  reported  all  3  of  the  following: 
1)  data  on  improved  patient  outcomes  in  the  control 
of  blood  pressure  (<140/90  mm  Hg)  and  cholesterol   
(<200  mm/dL  for  total  cholesterol  or  <100  mg/dL  for   
low-density lipoprotein cholesterol [LDL]), 2) incorpora-
tion of the interventions for at least 1 year, and 3) organi-
zational commitment to sustaining or institutionalizing 
the interventions. We made initial phone calls to gather 
information if it was not publicly available and then used 
the following criteria to rank and select 9 of the 34 PHPs: 
1) use of a control or comparison group in the study, 2) 
outcomes that were statistically or clinically significant, 
3) incorporation of national JNC 7 (20) and ATP III (21) 
guidelines, and 4) study populations that were at high 
risk for heart disease and stroke. Using in-depth tele-
phone interviews, we conducted a case study with key 
informants (physicians, other health-care practitioners, 
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and administrators) of the 9 PHPs selected in order to 
identify and learn about the factors and strategies that 
worked for establishing the PES interventions (73). The 
Centers for Disease Control and Prevention (CDC) taped 
and  transcribed  the  interviews  and  used  CDC  EZ-Text 
software  (provided  free  at  www.cdc.gov/hiv/software/ez-
text.htm) to code, categorize, and analyze responses to the 
interviews.
The  9  PHPs  were  the  Laurel  Health  System’s  CVD 
Collaborative  (Wellsboro,  Pennsylvania);  Health 
Management Corporation (Richmond, Virginia) for Blue 
Cross  Blue  Shield  (BCBS)  of  Delaware  (Wilmington, 
Delaware);  Kaiser  Permanente  (Cleveland,  Ohio);  Mayo 
Clinic’s  Division  of  Community  Internal  Medicine 
(Rochester, Minnesota); Robeson Healthcare Corporation’s 
CVD Collaborative (Lumberton, North Carolina); Midwest 
Heart Specialists (Chicago and Rockford, Illinois); MVP 
Health  Care  (Schenectady,  New  York,  and  Williston, 
Vermont); Drug Therapy Management, Inc (Pharmacist-
Managed Lipid Clinic, Greensboro, North Carolina); and 
Partners for Better Health of Health Partners (Minneapolis, 
Minnesota).
Results
The  Table  summarizes  the  PES  interventions  imple-
mented in each of the 9 PHPs included in our study, and 
we describe the study design and reported patient out-
comes in the Appendix. Four of the practices also reported 
their  outcome  data  for  high  blood  pressure  and  high 
cholesterol control in 5 studies in peer-reviewed journals 
(32,33,54,55,64). 
Key  informants  described  the  interventions  in  their 
PHPs, including 1) factors leading to their implementa-
tion, 2) models used in their design, 3) patient outcomes, 4) 
strategies for measuring progress, 5) costs, and 6) lessons 
learned.
Factors leading to interventions 
The  primary  reasons  PHPs  gave  for  implementing 
the interventions were the realization and concern that 
patients’ lipid concentrations (especially LDL cholesterol) 
or  blood  pressures  were  not  adequately  controlled,  as 
judged by using national guidelines (e.g., JNC 7 [20], ATP 
III [21]), and that the compliance of practice providers with 
these guidelines was inconsistent. This realization often 
stemmed  from  reviewing  patient  charts  and  evaluating 
the way health care was delivered within the informants’ 
organizations. Key informants reported that some practi-
tioners admitted that before they analyzed their patient 
charts, they had believed they were adequately following 
guidelines to help patients manage their conditions and 
were surprised to find they were not.
Some  key  informants  said  the  frequent  diagnoses  of 
heart  disease  within  their  patient  population  and  the 
related costly procedures led their organization to imple-
ment  PES  interventions.  Other  informants  said  they 
were influenced by data in the literature reporting on the 
U.S. burden of heart disease and the positive outcomes 
from  PES  interventions,  particularly  for  reducing  risk 
factors such as high cholesterol and high blood pressure. 
Informants  from  2  PHPs  mentioned  that  their  decision 
to  implement  interventions  was  influenced  by  changes 
in  the  health  care  commercial  market,  particularly  the 
move toward managed care, combined with their need to 
stay competitive. Practitioners in some PHPs introduced 
interventions that would help them more efficiently man-
age CVD in patients without adversely affecting the time 
spent  on  other  responsibilities.  Communities  were  the 
impetus behind some of the interventions. For example, a 
community group in Pennsylvania identified diabetes and 
CVD as major health problems in its community; because 
of the group’s commitment to reducing the impact of these 
diseases  in  the  community,  it  worked  with  the  Laurel 
Health System to spearhead and move its diabetes and 
cardiovascular collaboratives forward.
Descriptions of the interventions 
Key informants described a wide array of PES interven-
tions that had been implemented in their organizations, 
all of which were based on nationally recognized guidelines 
and  best  practices.  The  primary  types  of  interventions 
implemented  were  automated  physician  reminder  sys-
tems, specialized lipid clinics, collaboratives, and disease 
management programs (described below). The goals of the 
interventions centered on providing physicians with the 
tools to adequately treat patients with high blood pressure 
or high cholesterol, empowering patients with the skills to 
manage their conditions, achieving the goals referenced in 
the national guidelines, and, ultimately, preventing com-
plications related to CVD.
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into electronic medical records
Kaiser Permanente, Ohio, integrated physician remind-
ers into its electronic medical records system to support 
physician decision making at the time of each patient visit. 
This made it easier for physicians to access patient data 
during the visit, to be alerted when a patient’s cholesterol 
or  blood  pressure  was  uncontrolled,  to  determine  when 
testing for lipids or other purposes should be performed, 
and to adjust medications as needed.
Specialized lipid clinics 
Two PHPs used specialized lipid clinics to manage their 
patients’ cholesterol and triglyceride values. Lipid clinics 
provide  patient-focused  care  to  educate  patients  and  to 
assist them in setting self-management goals for changes 
in lifestyle. In addition, these clinics track patient status 
as measured by cholesterol values, medications prescribed, 
patient compliance with medication regimens, follow-up 
visits,  and  other  factors  that  determine  whether  com-
prehensive care is being offered. Some clinics also adjust 
medications based on evidence-based algorithms and the 
approval  of  the  physician.  Midwest  Heart  Specialists 
established  a  physician-directed  lipid  clinic  that  nurses 
managed  for  some  patients  with  high  cholesterol.  The 
results of this lipid clinic were so impressive (54) that the 
practice developed a virtual lipid clinic accessible to all 
providers that incorporated the process used in the nurse-
managed  clinic  into  an  electronic  record  system  with  a 
cholesterol management tool (55). The development of the 
virtual lipid clinic enabled patients from throughout the 
practice to benefit from this intervention. Drug Therapy 
Management, Inc, a pharmacist-managed lipid clinic con-
tracted with a cardiology clinic, also reported successful 
patient outcomes (33).
Collaboratives 
A collaborative is an integrated and collaborative nation-
al effort to eliminate disparities and improve health care 
delivery  systems.  Collaboratives  are  designed  to  help 
health care organizations improve the care of their patients 
with CVD and other chronic diseases. Collaboratives pro-
mote  evidence-based  health  care  strategies  for  quality 
improvement based on the Chronic Care Model and on 
the  Plan-Do-Study-Act  (PDSA)  cycles  described  below 
(74).  They  also  emphasize  sharing  experiences  among 
participating organizations to enable them to learn from 
one another. Three PHPs participated in a collaborative. 
Mayo Clinic’s Division of Community Internal Medicine 
in  Minnesota  participated  in  a  collaborative  sponsored 
by the Institute for Clinical Systems Improvement (ICSI) 
(www.icsi.org/).  As  part  of  this  collaborative,  this  PHP 
implemented  the  ICSI  Guidelines  (75)  for  blood  pres-
sure  control,  which  are  based  on  JNC-VI  guidelines 
(76),  and  redesigned  the  system  by  which  nurses  and 
medical assistants screened and managed patient blood 
pressure.  Robeson  Healthcare  Corporation  and  Laurel 
Health System implemented the Prevention of Diabetic 
and Cardiovascular Disease Collaborative of the Health 
Resources and Services Administration’s (HRSA’s) Bureau 
of Primary Care Health Disparities Collaboratives (www.
healthdisparities.net/hdc/html/collaborativesOverview.
aspx).
Disease management programs 
Three  PHPs  (Partners  for  Better  Health  of  Health 
Partners,  MVP  Health  Care,  Health  Management 
Corporation/BCBS  of  Delaware)  described  their  disease 
management programs for proactive, comprehensive man-
agement  of  their  patients  with  CVD.  Disease  manage-
ment programs, which are disease-specific, provide care 
by using such strategies as population identification pro-
cesses,  evidence-based  practice  guidelines,  collaborative 
practice models that include both physicians and providers 
of support services, patient self-management and educa-
tion, measurements of process and outcomes, evaluation 
and  management,  and  routine  reporting  and  feedback 
loops (77).
Health models used for designing interventions 
Four of the 9 PHPs incorporated the Chronic Care Model 
along  with  PDSA  cycles  for  quality  improvement  when 
designing their PES interventions. PDSA cycles rely on 
simple measurements to monitor the effect of small chang-
es over time, which then can build into larger improve-
ments through successive quick cycles of change. Although 
informants for the other 5 PHPs did not explicitly mention 
using the Chronic Care Model, their interventions often 
contained some of this model’s elements, such as use of 
protocols based on evidence-based guidelines, reorganiza-
tion  of  health  care  delivery,  use  of  clinical  information 
systems, and support for patient self-management.
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Two PHPs (Partners for Better Health of Health Partners 
and Health Management Corporation/BCBS of Delaware) 
modeled  their  patient  support  components  according  to 
where patients were on the health continuum:
One model that we’ve used is a model of the health 
continuum [that] describes what we’re trying to do 
with health improvement, and it goes from keeping 
people from advancing into stages of disease. So we 
look at our programs from primary prevention all 
the way through the care of the [patient] population 
with  the  highest  risk  and  mortality.  (informant, 
Partners for Better Health of Health Partners)
Such a model is patient-focused and approaches health 
promotion and prevention of risk factors at all stages of 
disease.  Along  these  lines,  some  PHPs  used  nurses  to 
regularly  interact  with  patients  via  telephone  or  other 
avenues to offer education and support.
Some  interventions  were  modeled  after  existing  pro-
grams  that  had  proven  successful.  For  example,  MVP 
Health Care implemented a CVD management program 
patterned  after  other  programs  already  in  place  for  its 
patients with asthma and diabetes.
Patient outcome data 
Patient outcome data for these PES interventions are 
limited to responses from the interviews with key infor-
mants (see Appendix) and the 5 studies reported in peer-
reviewed  journals  (32,33,54,55,64).  Informants  from  all 
PHPs reported that their interventions were very success-
ful  at  increasing  providers’  compliance  with  guidelines 
and  in  increasing  the  percentage  of  patients  who  met 
their cholesterol or blood pressure goals, complied with 
medication regimens, or set and achieved goals for self-
management. Informants also reported improvements in 
the delivery of health care, which led to an increase in the 
consistency and quality of patient care and more produc-
tive use of providers’ time. Some informants reported that 
these improvements decreased utilization of various forms 
of health care, such as inpatient admissions and emer-
gency room visits, and resulted in significant cost savings 
to health care plans.
Measuring progress 
Informants from the PHPs noted that they measured 
varying combinations of outcomes and processes for qual-
ity improvement. The indicators that the programs used 
to measure the various PES interventions are described 
below. Many informants stated that the organization must 
first agree on its definition of success:
Critical in our start was that we had to come to a 
common definition of success . . . not only [to] define 
success but also [to] measure success. And that was 
coming to agreement on the different . . . outcomes 
measures, process measures, and end results that 
would  define  our  success  for  everyone.  So  that 
we were all . . . going after the same goals. (infor-
mant,  Health  Management  Corporation/BCBS  of 
Delaware)
Outcomes measures 
Among  the  patient  outcome  measures  PHPs  reported 
were  monitoring  control  of  lipids,  glucose,  and  blood 
pressure among patients at risk and patients achieving 
self-management  goals,  such  as  weight  loss,  smoking 
cessation,  and  participation  in  regular  exercise.  Some 
PHPs also evaluated use of aspirin, angiotensin-convert-
ing enzyme inhibitors, and beta-blockers in patients with 
heart disease. Many PHPs also measured utilization rates 
for health care, such as emergency room visits, hospitaliza-
tions, and the pharmacy. In addition, Partners for Better 
Health  of  Health  Partners  monitored  the  percentage  of 
patients  who  had  all  modifiable  risk  factors  managed 
optimally. Drug Therapy Management, Inc, monitored the 
number of recurrent cardiovascular events, and Midwest 
Heart Specialists calculated the number of cardiovascular 
events prevented or lives saved.
Process measures 
Process measures included measuring physicians’ com-
pliance with policies and guidelines, patients’ compliance 
with medications and plans of care, and the percentage 
of patients screened for abnormal lipids, blood pressure, 
glucose, and glycosylated hemoglobin. PHPs that incorpo-
rated PDSA cycles conducted mini-studies to evaluate the 
effectiveness of each step of the intervention. For example, 
as part of redesigning the way it delivered patient care, 
Mayo Clinic delegated responsibility to licensed practical 
nurses (LPNs) and medical assistants (MAs) for taking 
patients’ blood pressure and referring patients with ele-
vated values for a follow-up visit with a registered nurse. 
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MAs, the clinic first monitored the number of times the 
LPN or MA successfully recognized high blood pressure 
and made the referral.
Choosing measures 
Informants  for  some  PHPs  explained  how  they  chose 
measures and why they chose to evaluate certain ones. 
They  chose  measures  they  believed  would  help  them 
improve the quality of care for patients, decrease expenses, 
or have the most impact on health outcomes. Often they 
chose to evaluate measures to help them comply with stan-
dards set by organizations such as the National Committee 
for Quality Assurance, HRSA’s Bureau of Primary Health 
Care, or the National Cholesterol Education Program.
We felt that we could make the most impact on the 
lipid profile, so we chose the lipid one [as an option-
al  parameter  to  measure].  (informant,  Robeson 
Healthcare Corporation)
Information systems 
Most PHPs used information technology systems to con-
tinuously monitor selected measures and to provide regu-
lar  feedback  to  health  care  practitioners,  organization 
management, or HRSA’s Bureau of Primary Health Care 
(Health Disparities Collaboratives). The feedback showed 
areas  in  need  of  improvement  and  indicated  whether 
goals  were  achieved.  The  PHPs  subsequently  used  the 
feedback to improve various components of the interven-
tion. One PHP informant described the use of statistical 
process control (SPC) to evaluate which processes needed 
improvement:
Using SPC, you could tell if some of the measures 
were  basically  more  than  2  standard  deviations 
from the desired goal. In which case, in SPC ter-
minology, that means you need to change your pro-
cesses. (informant, Kaiser Permanente, Ohio)
Barriers to measurements 
PHPs encountered some difficulties in measuring prog-
ress  or  success  of  interventions.  Among  these  were  a 
lack of resources for gathering necessary data, goals that 
proved too ambitious, and variation in physician behavior. 
Informants said they sometimes had problems with their 
computer systems. Some said that entering new patient 
data  skewed  all  previously  entered  measurement  data, 
making it difficult to evaluate improvements over time. 
They also said the lack of standardized codes for labora-
tory tests or other procedures sometimes made it difficult 
to merge data from different sources.
Costs of interventions 
When asked to estimate the financial costs of their PES 
interventions, PHP informants sometimes had difficulty 
assigning a total monetary value to the interventions. This 
was because many components of the interventions were 
phased in over a period of time, and others were incorpo-
rated into regular staff duties:
It’s really hard to answer that because it [the inter-
vention] becomes part of everybody’s work and it 
becomes  embedded  into  the  activities  across  the 
entire  spectrum  of  the  organization.  (informant, 
Partners for Better Health of Health Partners)
The costs of interventions included personnel time and 
resources  devoted  to  planning  and  goal  setting,  imple-
mentation of the interventions, and ongoing activities to 
sustain  the  interventions.  Some  interventions  involved 
significant time and effort for many people throughout the 
organization, often incurring substantial expenditures as 
measured by decreased time to devote to other services.
One informant described the many variables that could 
affect the cost of setting up a lipid clinic:
The [lipid] clinic costs are dependent on how they 
[are] set up. . . . The cost of putting in a system 
depends on what you’re doing. If you’re putting in 
a paper system, it costs almost nothing. If you put 
in a computer system, it can cost several thousand 
dollars per physician. (informant, Midwest Heart 
Specialists)
Some PHPs attempted to estimate the cost for certain 
components  of  their  interventions.  For  example,  the 
costs  ranged  from  $10,000  to  $15,000  for  a  pharmacy- 
managed lipid clinic to $700,000 for an automated medi-
cal records system with physician reminders for a patient 
population of approximately 300,000. Robeson Healthcare 
Corporation expressed the opinion that interventions were 
worth the cost if they ultimately prevented heart attacks, 
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strokes,  and  intensive  hospitalizations.  Midwest  Heart 
Specialists developed a virtual computer-based lipid clinic 
to  help  reduce  costs  associated  with  its  more  intensive 
nurse-managed lipid clinic.
Some informants said that the PES interventions, once 
implemented,  actually  increased  productivity  and  freed 
up time for physicians and other staff. For some interven-
tions, the costs were offset by help from other resources. 
For example, some PHPs received funds through special 
funding  grants  for  intervention  start-up  costs.  Health 
insurance companies enabled other interventions by reim-
bursing intervention services or by allowing their mem-
bers to have access to intervention programs. Because of 
their proven success with interventions, some PHPs have 
been able to negotiate better health insurance reimburse-
ment rates for intervention-related services.
Lessons learned and recommendations 
Key informants from the PHPs offered numerous recom-
mendations to those interested in implementing similar 
interventions.
Design and implementation of interventions 
• Generate awareness of the intervention among the staff, 
community (when applicable), and other stakeholders.
• Assure that all the stakeholders’ visions for the inter-
vention program are in alignment.
• Plan and organize details of the implementation, includ-
ing resources that will be needed.
• Develop a system for the performance of work processes 
and  integrate  these  processes  into  the  work  flow  for 
delivering  health  services.  Coordinate  the  operations 
among all the departments in the organization that will 
be involved with the interventions.
• Start small and persist; do not let desire for perfection be 
a stumbling block.
• Plan to sustain the interventions, which should include 
ongoing training for the staff.
Staffing 
• Get the right people on the health care team:
Pick people [who] are interested and enthusiastic 
to start with; don’t go for your toughest nuts first. 
(informant, Mayo Clinic)
• Interact with staff and other key players to communi-
cate how the protocols will work.
• Listen to and understand the needs of staff involved in 
implementing the interventions.
• Delegate work responsibilities to members of the health 
care team:
Get everyone on the team working at their maxi-
mum level. (informant, Mayo Clinic)
Patient focus 
• Provide  patient  education  with  a  focus  on  changing 
behaviors:
It’s  really  working  with  people  where  they  are 
and  moving  them  along  the  continuum  from   
inaction  to  actually  taking  action.  (informant, 
Health Management Corporation/BCBS)
• Foster relationships with patients:
[B]ecause  it  doesn’t  matter  if  you’re  really  intel-
ligent;  if  you  can’t  communicate  well  with  the 
patient and be congenial, friendly, and likable, then 
it’s not going to work well. The patient is not going 
to  follow  what  you  say.  I  think  that’s  what  has 
helped patients be compliant, is having someone 
that’s very caring and really concerned about them. 
(informant, Drug Therapy Management, Inc)
Discussion
On the basis of these case studies and reported outcome 
data, we concluded that practices that use comprehensive 
systems of patient care can be effective in controlling high 
blood pressure and high cholesterol. The PES interventions 
included 1) automated physician reminder systems, 2) spe-
cialized lipid clinics, 3) collaboratives, and 4) disease man-
agement programs. The common thread for these interven-
tions is that they all incorporated comprehensive systems 
for  patient  care  with  processes  that  were  well-defined, 
measurable,  and  linked  to  desirable  patient  outcomes. 
Most relied on data systems to identify patients targeted 
for the interventions and areas in need of improvement 
and to track progress. Most of them also included elements 
of the Chronic Care Model, and some said they used PDSA 
cycles to measure the effectiveness of each step of change.
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port for patient self-management and education, interven-
tions integrated easily into the daily work flow to make 
it  easier  for  staff  to  implement  them,  and  leadership 
and staff commitment. Other important factors included 
involving staff throughout the organization and commu-
nity groups in the planning and implementation stages, 
effective communication with health care providers and 
other staff, having ongoing training of staff, and keeping 
the intervention project high on the agenda so that moti-
vation for sustaining it would not be lost. Many of the key 
informants also noted the importance of enlisting the right 
people to be on the intervention team.
These PES interventions may not be applicable to all 
health care settings. Indeed, we note that the 9 PHPs we 
studied were often affiliated with larger health care plans 
that  could  afford  these  sometimes  costly  interventions. 
Smaller health care practices may not have the necessary 
resources.
Limitations and strengths of the case method 
Although most of the PHPs studied relied on noncon-
trolled evaluations, 4 of them used experimental or quasi-
experimental designs to evaluate the PES interventions. 
Although all of the information and data for this article 
were  gathered  through  an  interview  process,  4  of  the 
practices also reported their outcome data for high blood 
pressure and high cholesterol control in 5 studies in the 
peer-reviewed  literature  (32,33,54,55,64).  We  identified 
common  factors  among  the  PHPs  that  contributed  to 
their success in implementing the interventions, but this 
information was based on only 9 practices. Furthermore, 
our case method did not allow us to determine which PES 
interventions or combinations of interventions were most 
effective. We recommend a meta-analysis of PES interven-
tions in the literature.
Recommendations 
Further  research  is  needed  to  evaluate  the  effective-
ness of various PES interventions and to determine how 
smaller health care practices can adopt them. In addition, 
research is needed to determine the actual costs of put-
ting these systems in place and their impact on improving 
health  conditions.  Many  informants  were  not  aware  of 
the total costs of implementation. Health care executives 
may be hesitant to initiate similar interventions in their 
practices if the return on investment is uncertain. Studies 
are also needed to determine whether PES interventions 
can sustain positive patient outcomes, avert or delay heart 
disease or stroke, and improve patients’ health, quality of 
life, and productivity.
Conclusion 
The 9 PHPs we studied that used and institutionalized 
PES  interventions  for  at  least  1  year  reported  positive 
outcomes  for  controlling  high  blood  pressure  and  high 
cholesterol. We are among the first to use case studies to 
synthesize the practical experiences, lessons learned, and 
recommendations of PHPs using a variety of PES inter-
ventions. These results verify the value of PES interven-
tions reported in the literature, and they have important 
implications  for  clinicians  and  for  policy  makers.  The 
results show clinicians that certain strategies and factors 
are critical for establishing comprehensive systems of care, 
which can lead to positive patient outcomes. Policy makers 
may want to consider initiatives that require health care 
practices to adopt these systems of care.
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Table
Table. Policy, Environmental, and Systems-Level Interventions Implemented for Blood Pressure and Cholesterol Control 
Reported by Key Informants at 9 Health Care Practices, 2003a
Intervention KP DTM MHS Mayo RHC LHS HP HMC/BCBS MVP
Disease management program             • • •
Participation in collaborative       • • •      
Specialized lipid clinics   • •            
Automated physician reminders •   •   •        
Electronic medical records •   •         •  
National guidelines • • • • • • • • •
Patient education and self-management goals   • • • • • • • •
Nurse telephone lines     •     • • • •
Treatment protocols or algorithms   • •            
Patient tracking system or registry • • •   • • • • •
Patient flow sheets   • • • •        
Appointment reminders • • •           •
Multidisciplinary team     • • • •   •  
Progress reports or report cards     •   • • •   •
Chronic care model       • • • •    
Plan-Do-Study-Act cycles       • •   •    
Care delivery redesign     • • •        
 
KP indicates Kaiser Permanente, Cleveland, Ohio; DTM, Drug Therapy Management, Inc, Greensboro, North Carolina; MHS, Midwest Heart Specialists, 
Chicago and Rockford, Illinois; Mayo, Mayo Clinic, Division of Community Internal Medicine, Department of Medicine, Rochester, Minnesota; RHC, Robeson 
Healthcare Corporation, Lumberton, North Carolina; LHS, Laurel Health System, Wellsboro, Pennsylvania; HP, Health Partners Health Plan/Disease 
Management Program, Minneapolis, Minnesota; HMC/BCBS, Health Management Corporation, Richmond, Virginia/Blue Cross Blue Shield Delaware, 
Wilmington, Delaware; MVP, MVP Health Care, Schenectady, New York and Williston, Vermont. 
a Data were collected through telephone interviews with key informants (physicians, other health care practitioners, and administrators) at  participating 
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Outcomes of case study interviews with key informants for  health care 
practices were reported in studies published from 12 through 2002 and 
identified through a literature review by the authors (32,33,5,55,). 
Key informants at  health care organizations were interviewed in 2003. 
Following is a summary of these interviews arranged by intervention.
Automated Physician Reminder Systems Integrated Into 
Electronic Medical Records 
Practice: Kaiser Permanente, Cleveland, Ohio
Outcomes reported: Intervention group resulted in statistically significant 
improvement in cholesterol outcomes (). Study design was nonexperi-
mental; repeat cross-sectional design-time series.
Interview comment: 
“[T]here was better control of cholesterol levels in heart disease patients 
after we turned on [physician] reminders. . . . [At the end of 2001, there 
was] a 0% increase in cholesterol control. . . . [W]e’ve seen improvement 
in low-density lipoprotein (LDL) screening and control.”
Specialized Lipid Clinics 
Practice: Drug Therapy Management, Inc, Greensboro, North 
Carolina 
Outcomes reported: Intervention group resulted in statistically and clinical-
ly significant improvement in cholesterol outcomes compared with control 
group (33). Study design was quasi-experimental.
Interview comment: 
“[T]here are about 500 patients in the study. . . . [A]bout 3% [met] their 
LDL goal levels of less than 100 [mg/dL]. . . . So it’s been very successful.”
Practice: Midwest Heart Specialists, Chicago and Rockford, 
Illinois 
Nurse-Managed Lipid Clinic
Outcomes reported: Intervention group resulted in clinically significant 
improvement in cholesterol outcomes compared with control group (5). 
Study design was quasi-experimental.
Interview comment: 
“Following the initial evaluation, 71% of patients in the lipid clinic were at 
LDL goal, versus 22% of patients at LDL goal in the rest of the cardiology 
practice, and 11% of patients at goal in general practices throughout the 
country (at that time).”
Virtual Lipid Clinic
Outcomes reported: Intervention group resulted in clinically and statisti-
cally significant improvement in cholesterol outcomes compared with con-
trol group (55). Study design was experimental, with randomized selection 
of patients for intervention and control groups.
Interview comments:
“[L]ed to much higher quality patient care on a much more consistent basis 
practice-wide . . . very effective to a much larger group of patients.”
“Approximately 0% of patients are at LDL goal throughout the practice, 
including nurse-managed and virtual lipid clinics.”
Participation in Collaboratives 
Practice: Mayo Clinic, Division of Community Internal 
Medicine, Department of Medicine, Rochester, Minnesota 
Outcomes reported: Intervention group resulted in clinically and statisti-
cally significant improvement in outcomes for blood pressure (32). Study 
design was experimental.
Interview comments:
“We showed fairly consistently about a 5% difference in control rates 
between physicians using this model and physicians not using this model.”
“[W]e’ve seen sort of a sustained improvement in our control rates at least 
for the 3 or so initial years of this study. I think we went somewhere from 
about a baseline of 30% to somewhere up in about the 5% range.”
Practice: Robeson Healthcare Corporation, Lumberton, North 
Carolina 
Outcomes not published
Interview comments:
“Some of the more promising results of the collaborative are improve-
ment in the outcome measure of having blood pressure under control and 
improvements in self-management goal setting. Currently [2003], in our 
self-management goal setting for the cardiovascular registry . . . about  
3% of our [population of focus] has had a self-management goal set.  
. . . [On] the spread population, 35% of 3000 people have had a 
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self-management goal set. And that was something that 3 years ago we 
were not doing at all.”
In population of focus of 12 people during a period of 3 years, “5% of 
those people have a blood pressure under 10/0. I think the national 
average is around 20%, and we have been as high as 57%, which is 
almost 3 times that national average. And so that outcome measure, we 
have sustained that.”
“[I]f you look at our spread population, right now, we’re at 32% of 3000 
people . . . who have a blood pressure under control of 10/0. That 
number has been as high as 2%, but that was back when we had 1000 
people in the registry. So we’ve steadily climbed from [about] 15% up to 
32% over the last year while maintaining over 3000 people in that registry.”
Practice: Laurel Health System, Wellsboro, Pennsylvania 
Outcomes not published
Interview comments:
“[O]ne of our goals was [getting] patients’ blood pressure under 10/0 
mm Hg. The national goal is 50%. Right now we are at about 0% of our 
[population of focus] that have made goal.”
“[O]ur latest data [show that] we have 31 patients in the cardiovascular 
registry in that health center and approximately 0% are at goal, whereas 
the spread [population] is 1783, and they are a little over 50% [at goal], so 
their total is close to 50%.”
Disease Management Programs 
Practice: Health Partners Health Plan, Minneapolis, 
Minnesota 
Outcomes not published
Interview comment: 
“[W]e’ve seen a significant shift toward comprehensive care. . . . [A]re 
they getting their blood pressure in control and do they also have their lipid 
levels not only done but in control, and we’re actually measuring based on 
that whole picture and not just one component of that for a person. So we 
think best care equals having all of that done, and so it has gone up in the 
last few years, but it certainly has a long way to go.”
Practice: Health Management Corporation, Richmond, 
Virginia, for Blue Cross Blue Shield of Delaware, Wilmington, 
Delaware 
Outcomes not published
Interview comments:
“[H]ealth status and health process measures like getting the testing and 
the results, we see over time improvements in those areas. For example, 
the LDL testing which for diabetics should occur annually, over the course 
of 2 years that will typically shoot up, and meanwhile the value of the LDL, 
which you want to decrease, goes down. So those kinds of measures, we’re 
seeing improvement.”
“[We’ve seen] improvement in medication compliance.”
“We also do the SF-12 and the scores vary somewhat due to the condi-
tions as far as between mental health and the physical components. We’ll 
sometimes see more improvement in the mental health component with 
some conditions that are typically chronic, i.e., congestive heart failure.”
“[W]e also measure, where it’s appropriate, days of . . . lost activity, and 
we’ll see those drop pretty significantly over time.”
“[We’ve seen a] decrease in inpatient admission and inpatient hospital 
days, an increase in pharmacy utilization, a decrease in [emergency room] 
usage . . . there are usually significant cost savings.”
Practice: MVP Healthcare, Schenectady, New York, and 
Williston, Vermont 
Outcomes not published
Interview comment: 
“[Comparisons of] members who were in the program in the first half of 
2002 to those who were not [show] that of people in the program, 0.% 
had an LDL test within the year following their [hospital] discharge [versus] 
80.1% of those not in the program.”